journal
MENU ▼
Read by QxMD icon Read
search

Expert Review of Anticancer Therapy

journal
https://www.readbyqxmd.com/read/28649895/the-safety-and-efficacy-of-palbociclib-in-the-treatment-of-metastatic-breast-cancer
#1
Johannes Ettl, Nadia Harbeck
Palbociclib (Ibrance(®)) is the first-in-class CDK4/6 inhibitor which has been introduced into clinical practice for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC). It is an orally administered drug, which acts by selectively inhibiting cyclin-dependant kinases CDK4 and CDK6. Given together with anti-estrogens like letrozole and fulvestrant it enhances the antiproliferative effect of these drugs without compromising the favorable toxicity profile of endocrine therapy...
June 26, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28649882/neratinib-for-the-treatment-of-her2-positive-early-stage-breast-cancer
#2
Isabel Echavarria, Sara López-Tarruella, Iván Márquez-Rodas, Yolanda Jerez, Miguel Martin
Despite the advances in the treatment of HER2-positive breast cancer, resistance to actual chemotherapeutic regimens eventually occurs. Neratinib, an orally available pan-inhibitor of the ERBB family, represents an interesting new option for early-stage HER2-positive breast cancer. Areas covered: In this article, the development of neratinib, with a special focus on its potential value in the treatment of early-stage HER2-positive breast cancer, has been reviewed. For this purpose, a literature search was conducted, including preclinical studies, early-phase trials in advanced cancer with neratinib in monotherapy and in combination, and phase II and large phase III trials in the early setting...
June 26, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28649891/new-targeted-therapies-for-relapsed-pediatric-lymphoblastic-leukemia
#3
Joanna Pierro, Laura E Hogan, Teena Bhatla, William L Carroll
The improvement in outcomes for children with acute lymphoblastic leukemia (ALL) is one of the greatest success stories of modern oncology however the prognosis for patients who relapse remains dismal. Recent discoveries by high resolution genomic technologies have characterized the biology of relapsed leukemia, most notably pathways leading to the drug resistant phenotype. These observations open the possibility of targeting such pathways to prevent and/or treat relapse. Likewise, early experiences with new immunotherapeutic approaches have shown great promise...
June 25, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28636427/liver-directed-therapy-in-metastatic-colorectal-cancer
#4
Ciara M Kelly, Nancy E Kemeny
Colorectal cancer is a significant global health issue with over 1 million cases diagnosed annually throughout the world. 15% of patients diagnosed with colorectal cancer will have liver metastases and 60% will develop liver metastases if they have metastatic disease. Oligometastatic colorectal cancer confined to the liver represents an intermediate state in the evolution of metastatic capacity that opens the opportunity for local interventions. Area's covered: The literature supports long-term survival if patients undergo liver resection of colorectal metastases...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28635336/new-advances-in-focal-therapy-for-early-stage-prostate-cancer
#5
Kae Jack Tay, Ariel A Schulman, Christina Sze, Efrat Tsivian, Thomas J Polascik
Prostate focal therapy offers men the opportunity to achieve oncological control while preserving sexual and urinary function. The prerequisites for successful focal therapy are to accurately identify, localize and completely ablate the clinically significant cancer(s) within the prostate. We aim to evaluate the evidence for current and upcoming technologies that could shape the future of prostate cancer focal therapy in the next five years. Areas Covered: Current literature on advances in patient selection using imaging, biopsy and biomarkers, ablation techniques and adjuvant treatments for focal therapy are summarized...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28633552/cabozantinib-for-the-treatment-of-kidney-cancer
#6
Ahmed Abdelaziz, Ulka Vaishampayan
Cabozantinib is a small molecule tyrosine kinase inhibitor that initially showed activity in medullary thyroid cancer and was recently approved by the Food and Drug Administration for the treatment of metastatic renal cell carcinoma after progression on first line therapy. Areas Covered: In the METEOR trial, cabozantinib demonstrated significantly improved efficacy in all three endpoints; response rates, progression free survival and overall survival in a randomized trial with everolimus as an active comparator...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28621166/l-asparaginase-for-newly-diagnosed-extra-nodal-nk-t-cell-lymphoma-systematic-review-and-meta-analysis
#7
Vadim S Pokrovsky, Denis Vinnikov
OBJECTIVES: The aim of this review was to compare the efficacy of asparaginase (ASP)-containing vs ASP-absent regimens in the first-line treatment of ENKTL patients. METHODS: The PRISMA protocol was used to search PubMed and Embase for both controlled and uncontrolled studies of ASP or alternative chemotherapy (CT) for newly diagnosed ENKTL, published in English by March 2017. The regimens were compared to calculate relative risk (RR) with 95% confidence interval (CI) of the overall response rate (ORR), complete response (CR) or partial response (PR)...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28618843/risk-of-cardiac-death-among-cancer-survivors-in-the-united-states-a-seer-database-analysis
#8
Omar Abdel-Rahman
 Background: Population-based data on the risk of cardiac death among cancer survivors are needed. This scenario was evaluated in cancer survivors (>5 years) registered within the Surveillance, Epidemiology and End Results (SEER) database. METHODS: The SEER database was queried using SEER*Stat to determine the frequency of cardiac death compared to other causes of death; and to determine heart disease-specific and cancer-specific survival rates in survivors of each of the 10 most common cancers in men and women in the SEER database...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28597750/muc1-induces-tamoxifen-resistance-in-estrogen-receptor-positive-breast-cancer
#9
Parnaz Merikhian, Reyhane Ghadirian, Leila Farahmand, Sepideh Mansouri, Keivan Majidzadeh-A
Tamoxifen, as an essential therapeutic tool in the treatment of estrogen receptor-positive breast cancer, has been available for the past three decades and is currently being utilized as a chemo-preventive agent for patients at high risk for breast carcinoma. However, the induction of chemo-resistance during therapy has indicated a significant challenge with regards to this agent. Areas covered: This review enumerates the role of MUC1-C proto-oncogene in tamoxifen resistance and describes a number of signaling pathways by which MUC1-C would mediate the development of resistance...
June 21, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28604130/checkpoint-inhibitors-in-advanced-melanoma-effect-on-the-field-of-immunotherapy
#10
Aine O'reilly, James Larkin
The success of the immune checkpoint inhibitors in melanoma has reinvigorated the field of immunotherapy. Immune checkpoint inhibitors are now the standard of care in multiple cancer types including lung cancer, head and neck cancer, urothelial cancer and renal cell cancer. The field of immunotherapy is currently expanding rapidly and will be a focus of research and development for decades to come. Areas covered: This review covers the early development of immune checkpoint inhibitors and the changes that occurred in the drug development paradigm to facilitate the development of immunotherapy...
June 19, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28622054/down-regulation-of-liver-intestine-cadherin-enhances-noscapine-induced-apoptosis-in-human-colon-cancer-cells
#11
Xia Tian, Meng Liu, Qingxi Zhu, Jie Tan, Weijie Liu, Yanfen Wang, Wei Chen, Yanli Zou, Yishan Cai, Zheng Han, Xiaodong Huang
OBJECTIVES: Liver-intestine cadherin (CDH17) as a novel type of cadherin can significantly suppresses tumor growth in colon cancer cells. Noscapine is one of the most widely used antineoplastic agents in the treatment of solid tumor and haematological malignancies. The aim of the present study was to explore the signaling pathway of noscapine which induces apoptosis by blocking CDH17 gene in colon cancer SW480 cells. METHODS: Human colon cancer SW480 cells were transfected with CDH17 interference vector and treatment with 10 µmol/L noscapine...
June 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28621163/eribulin-in-advanced-liposarcoma-and-leiomyosarcoma
#12
Elisabetta Setola, Jonathan Noujaim, Charlotte Benson, Sant Chawla, Emanuela Palmerini, Robin L Jones
The heterogeneity of soft tissue sarcomas (STS) presents a formidable management challenge. Consequently, one of the main research goals is to define specific tailored therapy for each histological subtype and to develop a more personalised approach to treatment. The standard first line chemotherapy for advanced STS is doxorubicin, with or without ifosfamide, however, a number of different drugs are emerging as active therapies beyond first-line. Areas covered: Eribulin has recently been approved for advanced liposarcoma, after an anthracycline-containing regimen, demonstrating an overall survival (OS) advantage in liposarcoma and leiomyosarcoma in a randomised Phase III clinical trial...
June 16, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28594258/first-line-chemotherapy-with-pemetrexed-plus-cisplatin-for-malignant-peritoneal-mesothelioma
#13
Eriko Fujimoto, Takashi Kijima, Kozo Kuribayashi, Yoshiki Negi, Shingo Kanemura, Koji Mikami, Hiroshi Doi, Kazuhiro Kitajima, Takashi Nakano
BACKGROUND: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates the efficacy of first-line systemic pemetrexed and cisplatin chemotherapy in MPeM. RESEARCH DESIGN AND METHODS: Twenty-four patients with histologically proven MPeM were treated with pemetrexed plus cisplatin as a first-line systemic chemotherapy...
June 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28593803/impact-of-tumor-size-on-the-outcome-of-patients-with-small-renal-cell-carcinoma
#14
Omar Abdel-Rahman
BACKGROUND: ​This study aims to establish potential correlation between tumor size and outcomes in patients with T1a kidney cancer registered within the surveillance, epidemiology and end results (SEER) database. METHODS: SEER database (2004-2013) has been accessed through SEER*Stat program to determine the correlation between tumor size and cancer-specific survival in patients with T1a kidney cancer.  Survival analysis was conducted through Kaplan-Meier analysis and log-rank testing...
June 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28608763/identifying-clinical-risk-in-low-grade-gliomas-and-appropriate-treatment-strategies-with-special-emphasis-on-the-role-of-surgery
#15
Sébastien Boissonneau, Hugues Duffau
Diffuse low-grade glioma (DLGG) is a chronic tumoral disease that ineluctably grows, migrates along white matter pathways, and progresses to a higher grade of malignancy. Areas covered: To determine the best individualized treatment attitude for each DLGG patient, and to redefine it over the years, i.e. to optimize the "onco-functional balance" of serial and multimodal therapies, the understanding of the natural history of this chronic disease is crucial but not sufficient. A paradigmatic shift is to tailor the individual management according to the dynamic relationships between DLGG course and neural remodeling...
June 13, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28608762/limiting-the-morbidity-of-inguinofemoral-lymphadenectomy-in-vulvar-cancer-patients-a-review
#16
Anne-Floor W Pouwer, Henriette J Arts, Jacobus van der Velden, Joanne A de Hullu
Inguinofemoral lymphadenectomy (IFL) is performed in the treatment for vulvar cancer. One or more complications after IFL is reported in up to 85% of the patients. This review presents an overview of surgical techniques and peri- and post-operative care that has been studied in order to reduce the morbidity associated with IFL in vulvar cancer patients. Areas covered: Current knowledge on post-operative complications after different surgical techniques and peri- and post-operative protocols were discussed. A systematic literature review was conducted using MEDLINE, EMBASE and the Cochrane library on 20 February 2017...
June 13, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28580808/regorafenib-for-the-treatment-of-unresectable-hepatocellular-carcinoma
#17
Lorenza Rimassa, Tiziana Pressiani, Nicola Personeni, Armando Santoro
Sorafenib is the standard of care for patients with advanced hepatocellular carcinoma (HCC) and well preserved liver function. However, until recent approval of regorafenib by the Food and Drug Administration (FDA), no effective therapeutic options were available for patients resistant to sorafenib. Areas covered: The present article reviews the preclinical and clinical data of regorafenib, putting them into the context of current and future landscape of treatment options for patients with HCC. Recently, the randomized, placebo-controlled, Phase III RESORCE trial, demonstrated a statistically and clinically significant increase in overall survival from 7...
June 9, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28537815/anticancer-treatments-and-female-fertility-clinical-concerns-and-role-of-oncologists-in-oncofertility-practice
#18
Mahmoud Salama, Teresa K Woodruff
Anticancer treatments such as aggressive chemotherapy and radiotherapy have deleterious gonadotoxic side effects and are considered the most common causes of pathological and iatrogenic fertility loss in women. Areas covered: In order to preserve fertility of young women and girls with cancer, several established, experimental, and debatable options can be offered in the emerging field of oncofertility. This article reviews the effects of anticancer treatments on female fertility and discusses the current challenges and future directions of fertility preservation options that can be offered to the female patients with cancer...
June 5, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28532278/tackling-non-metastatic-castration-resistant-prostate-cancer-special-considerations-in-treatment
#19
Archana Anantharaman, Eric J Small
Prostate cancer (PCa) is currently the second most common cancer affecting men worldwide. Metastatic castration-resistant prostate cancer (mCRPC) is the incurable form of PCa, carrying the poorest prognosis, and can develop from non-metastatic CRPC (M0 CRPC). CRPC is defined as progression of the disease with castrate level testosterone levels, achieved with primary androgen deprivation therapy (ADT). M0 CRPC is a highly heterogeneous disease process lacking clear standard of care therapies. Areas covered: In this review, a broad literature search was undertaken to explore data available for therapeutic options and guidelines in the management of M0 CRPC...
May 31, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28506194/the-use-of-systemic-therapies-to-prevent-progression-of-inflammatory-breast-cancer-which-targeted-therapies-to-add-on-cytotoxic-combinations
#20
Anthony Gonçalves, Audrey Monneur, Patrice Viens, François Bertucci
Inflammatory breast cancer is a rare but frequently fatal disease, essentially because of its high ability to develop distant metastases. Even though the prognosis of IBC was significantly improved by multimodal management, including the systematic use of cytotoxic-based induction, the prognosis remains largely dismal. Areas covered: This review presents the main achievements in the systemic treatment of IBC during the past 30 years. It focuses more specifically on recent results obtained with targeted therapies, including anti-HER2 and anti-angiogenic agents...
May 25, 2017: Expert Review of Anticancer Therapy
journal
journal
39793
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"